Cargando…

Inflammasome in Skeletal Muscle: NLRP3 Is an Inflammatory Cell Stress Component in Inclusion Body Myositis

Inclusion body myositis (IBM) is a chronic, mostly treatment-resistant, inflammatory myopathy with a pathology that centers around specific interactions between inflammation and protein accumulation. The study aimed to identify the inflammasome as a key event in the complex network of pathomechanism...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kummer, Karsten, Bertram, Imke, Zechel, Sabrina, Hoffmann, Daniel B., Schmidt, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342058/ https://www.ncbi.nlm.nih.gov/pubmed/37445853 http://dx.doi.org/10.3390/ijms241310675

Ejemplares similares

Skeletal muscle fibers produce B-cell stimulatory factors in chronic myositis
por: Carstens, Per-Ole, et al.
Publicado: (2023)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany
por: Senn, Katja C., et al.
Publicado: (2023)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis
por: Murakami, Ayuka, et al.
Publicado: (2022)

A protocol to develop clinical guidelines for inclusion‐body myositis
por: Jones, Katherine L., et al.
Publicado: (2016)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis
por: Dubourg, O., et al.
Publicado: (2011)

Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis
por: Ikenaga, Chiseko, et al.
Publicado: (2022)

Development and validation of a Bayesian survival model for inclusion body myositis
por: Capkun, Gorana, et al.
Publicado: (2019)

Inflammasome in ALS Skeletal Muscle: NLRP3 as a Potential Biomarker
por: Moreno-García, Leticia, et al.
Publicado: (2021)

The role of NLRP3 inflammasome in inflammation-related skeletal muscle atrophy
por: Liu, Yukun, et al.
Publicado: (2022)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Induction of Osmolyte Pathways in Skeletal Muscle Inflammation: Novel Biomarkers for Myositis
por: De Paepe, Boel, et al.
Publicado: (2018)

Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis
por: Salajegheh, Mohammad, et al.
Publicado: (2011)

Diagnostic Value of Muscle [(11)C] PIB-PET in Inclusion Body Myositis
por: Noto, Yu-ichi, et al.
Publicado: (2020)

Effects of long-term resistance exercise training on autophagy in rat skeletal muscle of chloroquine-induced sporadic inclusion body myositis
por: Kwon, Insu, et al.
Publicado: (2015)

The effect of systematic exercise training on skeletal muscle strength in a patient with advanced inclusion body myositis: A case study
por: D’Alton, C, et al.
Publicado: (2022)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Dysphagia as the Presenting Symptom for Inclusion Body Myositis
por: Esteban, Marcus Juan, et al.
Publicado: (2021)

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Patient-Reported Health-Related Quality of Life, Anxiety and Depression in Patients with Inclusion Body Myositis: A Register-Based Cross-Sectional Study in Germany
por: Senn, Katja C., et al.
Publicado: (2023)

The NLRP3 inflammasome contributes to inflammation‐induced morphological and metabolic alterations in skeletal muscle
por: Eggelbusch, Moritz, et al.
Publicado: (2022)

Sporadic inclusion body myositis: the genetic contributions to the pathogenesis
por: Gang, Qiang, et al.
Publicado: (2014)

Mitochondrial and inflammatory changes in sporadic inclusion body myositis
por: Rygiel, Karolina A., et al.
Publicado: (2015)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis
por: de Camargo, Leonardo Valente, et al.
Publicado: (2018)

CYLD dysregulation in pathogenesis of sporadic inclusion body myositis
por: Yamashita, Satoshi, et al.
Publicado: (2019)

Inclusion body myositis in a patient with rheumatoid arthritis
por: Tariq, Mohammad, et al.
Publicado: (2018)

Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis?
por: Zakaria, Ali, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s2k56ulrjtdda82coraue3m1j4